Addressing social and cultural drivers of type 2 diabetes is key to its treatment and prevention

Novo NordiskNew research shows healthcare services and public health strategies aimed at reducing the burden of type 2 diabetes may prove ineffective, unless they address social and cultural factors.(1) Researchers linked factors such as food traditions and traditional gender roles to increasing vulnerability to diabetes in cities(1), where three-quarters of people with the disease are set to live by 2045.(3) The findings from the Cities Changing Diabetes research were presented at the 54th Annual Meeting of the European Association for the Study of Diabetes (EASD 2018) in Berlin, Germany.

"For many years, diabetes has continued to rise at an alarming rate despite the best efforts of policymaker and healthcare providers," says David Napier, professor of Medical Anthropology at University College London (UCL). "In order to turn the table on this devastating and costly disease, we need to think differently and adopt new approaches. When public health strategies and individual care plans take into account the prevailing local cultures and associated conventions and behaviours, they are much more likely to be successful."

Fuelled by rapidly increasing rates of obesity, diabetes could affect one in nine adults by 2045 - more than 730 million people.(2) Within the same time frame, annual diabetes-related healthcare costs are expected to increase by 39% from 775 billion US dollars to more than 1 trillion dollars, further highlighting the urgency for action.(4)

Within their findings, researchers pointed to a number of social and cultural factors contributing to the rise of diabetes in cities around the world, including:(1)

  • In Copenhagen, standard medical referral practices acting as barriers to preventive care and services for diabetes
  • In Houston, food traditions becoming entwined with heritage and culture and often being perceived as providing 'comfort'
  • In Mexico City, traditional gender roles limiting effective self-care in male-only households, as some men are unable or unwilling to provide diabetes support to others

A second study presented by Cities Changing Diabetes researchers at EASD 2018 demonstrated that rates of diabetes and obesity are accelerating in every region of the world today. North America and Europe, where obesity has been rising for decades, are expected to have the highest future type 2 diabetes prevalence but also the slowest future increases.(5) Africa, on the other hand, is projected to see a near-threefold increase in the number of people living with diabetes as the population ages and obesity prevalence increases.(5) Achieving a 25% reduction of obesity prevalence on the continent would result in 15.3 million fewer people with type 2 diabetes in 2045.(5)

"Whether it's by initiating door-to-door care provision, relocating clinics within urban communities or through enabling peer support among religious faith groups, the many partners in the Cities Changing Diabetes programme are already acting to great effect on these research findings," said Niels Lund, vice president for Health Advocacy, Novo Nordisk. "However, halting the rise of diabetes requires others to learn from their approach and to develop strategies that reflect local needs. To this end, the Cities Changing Diabetes programme is an open and inclusive partnership in which anyone with a stake in the prevention and treatment of diabetes is welcome to participate."

About the studies

The first study carried out Vulnerability Assessments in five highly diverse cities - Copenhagen, Houston, Mexico City, Shanghai and Tianjin - to assess the impact of cultural factors on vulnerability to type 2 diabetes. This included traditions and conventions, health beliefs and food practices, gender attitudes, and local practices to care seeking. Using semi-structured interviews, assessments were conducted with a total of 740 people.(1)

The second study investigated the regional prevalence of type 2 diabetes from 2017-2045, using past and target trend scenarios. The past trend scenario assumes that future increase in obesity prevalence is extrapolated linearly, and in a target scenario obesity prevalence is reduced by 25% in 2045. BMI data for all countries worldwide 2000-2014 were obtained from the Non-communicable Disease Risk Factor Collaboration, and the share of people in each age and BMI class were projected depending on scenario.(5)

About Cities Changing Diabetes

Cities Changing Diabetes is a first-of-its-kind partnership programme with an ambitious global goal to reduce obesity by 25% so that only 1 in 10 people live with diabetes by 2045. More than 100 local partners - including city leaders and ministries, academia, diabetes associations, health insurers, community groups and business corporations - collaborate across disciplines and in new forms of public-private partnerships to map the diabetes problem, share solutions and drive actions to bend the curve on urban diabetes.

The programme was initiated in 2014 by three global partners: University College London, Steno Diabetes Center Copenhagen and Novo Nordisk. Today, 17 cities representing more than 130 million citizens are active partners: Beijing, Beirut, Buenos Aires, Copenhagen, Hangzhou, Houston, Jakarta, Johannesburg, Koriyama, Leicester, Mérida, Mexico City, Rome, Shanghai, Tianjin, Vancouver and Xiamen.

About Novo Nordisk

Novo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 43,100 people in 79 countries and markets its products in more than 170 countries.

1. Volkmann A-M, Hesseldal L, Bagger M, et al. Local traditions and conventions impact vulnerability to type 2 diabetes. Abstract presented at the 54th Annual Meeting of the European Association for the Study of Diabetes (EASD), Berlin, Germany; 1-5 October 2018.
2. Moses A, Lund N, Jensen BB, et al. Illustrating the pivotal role of obesity as a driver of diabetes. Abstract presented at the 25th European Congress on Obesity (ECO 2018), Vienna, Austria; 23-26 May 2018.
3. International Diabetes Federation. IDF Diabetes Atlas, 7 ed. Brussels, Belgium: International Diabetes Federation; 2015.
4. Cities Changing Diabetes. Diabetes Projection Model, Global. Data on file. Novo Nordisk. In: Incentive, ed. Holte, Denmark; 2017.
5. Nielsen S, Napier D, Jensen BB, et al. Regional burden of obesity and diabetes in adults - projections from 2017-2045. Abstract presented at the 54th Annual Meeting of the European Association for the Study of Diabetes (EASD), Berlin, Germany; 1-5 October 2018.

Most Popular Now

Therapy using dual immune system cells effectively…

A newly developed immunotherapy that simultaneously uses modified immune-fighting cells to home in on and attack two antigens, or foreign substances, on cancer cells was ...

How to develop new drugs based on merged datasets

Polymorphs are molecules that have different molecular packing arrangements despite identical chemical compositions. In a recent paper, researchers at GlaxoSmithKline (GS...

New drug combination effective against SARS-CoV-2 …

More countries with greater resources are opening up for a more normal life. But COVID-19 and the SARS-CoV-2 virus are still a significant threat in large parts of the wo...

Cleveland Clinic study suggests steroid nasal spra…

A recent Cleveland Clinic study found that patients who regularly use steroid nasal sprays are less likely to develop severe COVID-19-related disease, including a 20 to 2...

Sanofi to focus its COVID-19 development efforts o…

Recent positive interim results of Sanofi's mRNA-based COVID-19 vaccine candidate Phase 1/2 study confirm the company's platform robust capabilities and strategy in mRNA...

Discovery of mechanics of drug targets for COVID-1…

A team of international researchers, including McGill Professor Stéphane Laporte, have discovered the working mechanism of potential drug targets for various diseases suc...

Phase II/III trial shows Ronapreve™ (casirivimab a…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive data from the phase II/III 2066 study, investigating Ronapreve™ (casirivimab and imdevimab) in patients hospit...

Pfizer and BioNTech receive first U.S. FDA Emergen…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the U.S. Food and Drug Administration (FDA) has authorized for emergency use a booster dose of the P...

AZD7442 request for Emergency Use Authorization fo…

AstraZeneca has submitted a request to the US Food and Drug Administration (FDA) for an Emergency Use Authorization (EUA) for AZD7442, its long-acting antibody (LAAB) com...

Pfizer and BioNTech receive CHMP positive opinion …

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the Europea...

Boehringer Ingelheim acquires Abexxa Biologics to …

Boehringer Ingelheim announced the acquisition of Abexxa Biologics Inc., a biopharmaceutical company taking a new approach in the fields of immuno-oncology and oncology r...

GSK welcomes WHO recommendation for broad roll-out…

GlaxoSmithKline (GSK) plc welcomes and applauds the WHO recommendation for the broader deployment of GSK's RTS,S malaria vaccine to reduce childhood illness and deaths fr...